TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

RNS Number : 5250L

ReNeuron Group plc

13 August 2013

 

13 August 2013

AIM: RENE

ReNeuron Group plc

(the "Company")

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:			ReNeuron Group plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation:		Abingworth LLP Abingworth Bioventures VI LP Abingworth Bioequities Master Fund Limited
4. Full name of shareholder(s)  (if different from 3.):		Bank of New York (Nominees) Limited (as nominee for Abingworth Bioventures VI LP) Jefferies & Co Inc. (as nominee for Abingworth Bioequities Master Fund Limited)
5. Date of the transaction and date on which the threshold is crossed or reached:		9 August 2013
6. Date on which issuer notified:		12 August 2013
7. Threshold(s) that is/are crossed or reached:		Above 5% threshold - Abingworth LLP Above 4% threshold - Abingworth Bioequities Master Fund Limited

8. Notified details: Abingworth LLP

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights

Direct

Direct

Indirect

Direct

Indirect

ReNeuron Group plc ISIN number GB00B0DZML60

0

0

90,000,000

5.03%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

90,000,000

5.03%

8. Notified details: Abingworth Bioequities Master Fund Limited

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights

Direct

Direct

Indirect

Direct

Indirect

ReNeuron Group plc ISIN number GB00B0DZML60

0

0

80,000,000

80,000,000

4.47%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

80,000,000

4.47%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
Abingworth Bioventures VI LP (which holds 10,000,000 shares in the company (0.56%)) and Abingworth Bioequities Master Fund Limited (which holds 80,000,000 shares in the company (4.47%)) are both managed by Abingworth LLP.
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:	John Heard
15. Contact telephone number:	0207 534 1508

 

END

 

 

HOLLLFLRTEIFLIV